Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome Gefitinib-resistance in non-small cell lung cancer cell lines
H Li(Shanghai Pulmonary Hospital), Caicun Zhou(Tongji University), Xiaoyu Yang(Second Affiliated Hospital of Jilin University), Bin Su(Shanghai Pulmonary Hospital), Yan Zhao(Tongji University), Gerald Schmid‐Bindert(Heidelberg University), D Wang(Tongji University)
Cited by 85
Related Papers
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
|Clinical Cancer Research|2015|469
Micromolding of photocrosslinkable chitosan hydrogel for spheroid microarray and co-cultures
|Biomaterials|2006|330
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311